Business OpportunitiesSimayla becomes 100% Zydus subsidiary
Drug firm Zydus Cadila today said it has acquired the remaining 30 per cent stake in its South Africa-based subsidiary Simayla for an undisclosed amount.
- GTL promoter hikes stake to 47.8% - Govt may hike stake in few public sector banks - HC stops Zydus drug sale on Sun petition - Zydus Cadila net up 39% to Rs 132 cr - Everest in talks with Zydus, Adani for pre-engineered buildings - Zydus Infra"s knowledge park to come up in 500 hectares
Zydus Cadila, through its South African subsidiary Zydus Healthcare SA, has acquired the remaining 30 per cent stake from the co-promoters of Simayla Pharmaceuticals (Proprietary), the company said in a filing to the Bombay Stock Exchange.
Zydus Healthcare SA had bought majority stake of 70 per cent in Simayla in 2008 and after this development, the African company would become a 100 per cent arm subsidiary of Zydus group, the company said.
"We will be stepping up our plans for growth in line with our global strategies and looking at long term initiatives that reaffirm our commitment of being an ethical healthcare provider," Zydus Cadila Chairman and Managing Director Pankaj R Patel said.
Simayla has strong presence in the cardio vascular, anti-infective, respiratory, gastrointestinal and women"s healthcare segment and is synergistic fit for the Zydus group, the company said.